MOORESVILLE, N.C., Feb. 28, 2023 /PRNewswire/ -- Novant Health has signed a definitive agreement to acquire Lake Norman Regional Medical Center, Davis Regional Medical Center and their related businesses, including physician clinic operations and outpatient services from subsidiaries of Community Health Systems, Inc. (NYSE: CYH).
"Our shared commitments to the community will continue to anchor our efforts and plans as we deliver exceptional, patient-centered experiences; protect safety and quality; improve community health; and promote equitable access to care," said Carl S. Armato, president and CEO of Novant Health. "This unique and exciting opportunity to extend Novant Health's regional delivery network to new communities also creates opportunities for medical education, research and innovation."
The transaction is subject to regulatory approvals and is expected to close later this year.
"Novant Health has a demonstrated commitment to delivering quality care to the patients they serve across the communities they serve," said Matthew Littlejohn, Chief Executive Officer of Lake Norman Regional Medical Center and Davis Regional Medical Center. "Our tradition of serving the community with medical services close to home will be enhanced thanks to the dedication and skill of our medical staff and employees."
Once the transaction is complete, Novant Health will continue working with employees, members of the medical staff, and other stakeholders to deliver quality care close to home.
Last Trade: | US$4.05 |
Daily Change: | -0.27 -6.25 |
Daily Volume: | 1,702,134 |
Market Cap: | US$562.710M |
September 16, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB